BG60797B2 - Сол на(1-бензил-1н-индазол-3-ил)оксиоцетна киселина с лизин и метод за получаването й - Google Patents

Сол на(1-бензил-1н-индазол-3-ил)оксиоцетна киселина с лизин и метод за получаването й Download PDF

Info

Publication number: BG60797B2
Authority: BG; Bulgaria
Prior art keywords: lysine; salt; benzyl; oxyacetic acid; bendazac
Prior art date: 1980-07-29

Application number

BG098555A

Other languages

Bulgarian (bg)

English (en)

Inventor

Bruno Silvestrini

Leandro Baiocchi

Original Assignee

Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-07-29

Filing date

1994-02-24

Publication date

1996-03-29

1994-02-24 Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.

1996-03-29 Publication of BG60797B2 publication Critical patent/BG60797B2/bg

Links

239000004472 Lysine Substances 0.000 title claims abstract description 13
150000003839 salts Chemical class 0.000 title claims abstract description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 10
238000002360 preparation method Methods 0.000 title claims description 3
238000000034 method Methods 0.000 title claims 2
239000002253 acid Substances 0.000 title abstract description 10
BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 claims abstract description 23
230000036765 blood level Effects 0.000 claims abstract description 5
230000001225 therapeutic effect Effects 0.000 claims abstract description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 2
238000001816 cooling Methods 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
238000001035 drying Methods 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
239000002244 precipitate Substances 0.000 claims 1
229960005149 bendazac Drugs 0.000 abstract description 9
201000004624 Dermatitis Diseases 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
235000018977 lysine Nutrition 0.000 description 4
235000019766 L-Lysine Nutrition 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
150000008545 L-lysines Chemical class 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
-1 alkaline earth metal salts Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
125000004245 indazol-3-yl group Chemical group [H]N1N=C(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG098555A 1980-07-29 1994-02-24 Сол на(1-бензил-1н-индазол-3-ил)оксиоцетна киселина с лизин и метод за получаването й BG60797B2 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT23768/80A IT1131779B (it)	1980-07-29	1980-07-29	Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione

Publications (1)

Publication Number	Publication Date
BG60797B2 true BG60797B2 (bg)	1996-03-29

Family

ID=11209809

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG098555A BG60797B2 (bg)	1980-07-29	1994-02-24	Сол на(1-бензил-1н-индазол-3-ил)оксиоцетна киселина с лизин и метод за получаването й

Country Status (17)

Country	Link
US (1)	US4352813A (es)
JP (1)	JPS5753465A (es)
AR (1)	AR227677A1 (es)
AU (1)	AU536243B2 (es)
BE (1)	BE891914A (es)
BG (1)	BG60797B2 (es)
CA (1)	CA1166643A (es)
CH (1)	CH651556A5 (es)
DE (1)	DE3202561A1 (es)
ES (1)	ES503509A0 (es)
FR (1)	FR2489318B1 (es)
GB (1)	GB2081708B (es)
IT (1)	IT1131779B (es)
MX (1)	MX156471A (es)
NL (1)	NL8200222A (es)
PT (1)	PT73365B (es)
SE (2)	SE455306B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1189052B (it) *	1981-11-27	1988-01-28	Acraf	Trattamento della cataratta
IT1194564B (it) *	1983-04-18	1988-09-22	Acraf	Impiego del bendazac e dei suoi sali nel trattamento della retinite pigmentosa
IT1230441B (it)	1989-02-07	1991-10-23	Acraf	Eteri della serie dell'indazolo
IT1229674B (it) *	1989-04-26	1991-09-06	Acraf	Composizione farmaceutica per uso topico oftalmico contenente bendazac o 5-0h bendazac
US5217983A (en) *	1992-03-27	1993-06-08	Du Pont Merck Pharmaceutical Company	(N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
US5272169A (en) *	1992-03-27	1993-12-21	The Dupont Merck Pharmaceutical Company	(N-benzyl) acetaldehyde bicyclic heterocycles useful as topical antiinflammatories
IT1293794B1 (it) *	1997-07-28	1999-03-10	Acraf	Farmaco attivo nel ridurre la produzione di proteina mcp-1
ITMI20062254A1 (it) *	2006-11-24	2008-05-25	Acraf	Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
CN103641784B (zh) *	2013-12-03	2018-06-19	杭州民生药业有限公司	一种苄达赖氨酸合成工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1530097A (fr)	1966-08-29	1968-06-21	Acraf	Acides indazole-3-yl-oxyalcanoïques et procédé pour leur préparation
IL28032A (en) *	1966-08-29	1971-08-25	Acraf	Indazol-3-yl-oxyalkanoic acids and process for the preparation thereof
NL6717184A (es) *	1967-12-16	1969-06-18	Stamicarbon
FR2217003A1 (en) *	1973-02-14	1974-09-06	Inst Investigaciones Terapeuti	Benzopyrilacetic acid deriv prepn - by reacting 1-(p-chlorobenzoyl-2-methyl)-5-methoxy-benzopyrilacetic acid with a base
DE2940373A1 (de) *	1979-10-05	1981-04-23	Troponwerke GmbH & Co KG, 5000 Köln	Lysin-(1-(p-chlorbenzoyl)-5-methoxy-2-methyl-3-indol) -acetoxy-acetate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

1980
- 1980-07-29 IT IT23768/80A patent/IT1131779B/it active Protection Beyond IP Right Term
1981
- 1981-06-02 US US06/269,923 patent/US4352813A/en not_active Expired - Lifetime
- 1981-06-18 GB GB8118767A patent/GB2081708B/en not_active Expired
- 1981-06-23 MX MX187939A patent/MX156471A/es unknown
- 1981-06-29 ES ES503509A patent/ES503509A0/es active Granted
- 1981-07-14 PT PT73365A patent/PT73365B/pt unknown
- 1981-07-15 AR AR286096A patent/AR227677A1/es active
- 1981-07-27 FR FR8114549A patent/FR2489318B1/fr not_active Expired
- 1981-07-28 JP JP56119033A patent/JPS5753465A/ja active Granted
1982
- 1982-01-21 NL NL8200222A patent/NL8200222A/nl not_active Application Discontinuation
- 1982-01-26 CA CA000394976A patent/CA1166643A/en not_active Expired
- 1982-01-26 CH CH457/82A patent/CH651556A5/fr not_active IP Right Cessation
- 1982-01-27 SE SE8200424A patent/SE455306B/sv not_active IP Right Cessation
- 1982-01-27 BE BE0/207152A patent/BE891914A/fr not_active IP Right Cessation
- 1982-01-27 AU AU79870/82A patent/AU536243B2/en not_active Ceased
- 1982-01-27 DE DE19823202561 patent/DE3202561A1/de active Granted
1983
- 1983-05-04 SE SE8302552A patent/SE8302552L/xx not_active Application Discontinuation
1994
- 1994-02-24 BG BG098555A patent/BG60797B2/bg unknown

Also Published As

Publication number	Publication date
DE3202561A1 (de)	1983-08-04
GB2081708A (en)	1982-02-24
ES8203850A1 (es)	1982-04-01
PT73365A (en)	1981-08-01
CH651556A5 (en)	1985-09-30
US4352813A (en)	1982-10-05
GB2081708B (en)	1984-06-20
JPS5753465A (en)	1982-03-30
CA1166643A (en)	1984-05-01
IT8023768A0 (it)	1980-07-29
MX156471A (es)	1988-08-26
NL8200222A (nl)	1983-08-16
AU7987082A (en)	1983-08-04
SE8302552D0 (sv)	1983-05-04
AR227677A1 (es)	1982-11-30
ES503509A0 (es)	1982-04-01
JPH0322384B2 (es)	1991-03-26
FR2489318A1 (fr)	1982-03-05
SE8302552L (sv)	1983-07-28
BE891914A (fr)	1982-05-17
FR2489318B1 (fr)	1986-01-03
IT1131779B (it)	1986-06-25
SE455306B (sv)	1988-07-04
AU536243B2 (en)	1984-05-03
PT73365B (en)	1982-09-23
SE8200424L (sv)	1983-07-28

Publication	Publication Date	Title
JPH0524135B2 (es)	1993-04-06
CZ286621B6 (cs)	2000-05-17	Tromethaminová sůl (+)-(S)-2-(3-benzoylfenyl)propionové kyseliny, způsob její výroby a farmaceutický prostředek s jejím obsahem
JPH06183973A (ja)	1994-07-05	Ｌ−２−オキソチアゾリジン−４−カルボキシレートのエステルを用いるグルタチオン細胞内合成の刺激方法
BG60797B2 (bg)	1996-03-29	Сол на(1-бензил-1н-индазол-3-ил)оксиоцетна киселина с лизин и метод за получаването й
BG62066B2 (bg)	1999-01-29	(s)-(-)-1-пропил-2',6'-пипеколоксилидидов хидрохлорид монохидрат, метод за получаването му и фармацевтичен препарат, който го съдържа
JP2815179B2 (ja)	1998-10-27	抗炎症および／または抗アレルギー剤
EP0186252A2 (en)	1986-07-02	Use of thiophene compounds for the manufacture of a medicament against tumours
JPS591458A (ja)	1984-01-06	ベンズヒドリルスルフイニルアセトヒドロキサム酸誘導体、その製造方法およびこの誘導体を有効成分とする中枢神経系治療剤
US4472387A (en)	1984-09-18	Pharmaceutical compositions capable of increasing cerebral serotonin concentration
JPS6117574A (ja)	1986-01-25	カルシウム拮抗活性のある１‐〔ビス‐（４‐ルオロフエニル）‐メチル〕‐４‐（３‐フエニル‐２‐プロペニル）‐ヘキサヒドロ‐１ｈ‐１，４‐ジアゼピンとその製法及びそれを含有する医薬組成物
JPS6133816B2 (es)	1986-08-04
KR880001477B1 (ko)	1988-08-13	니플룸산 모르폴리노에틸에스테르 디니플루메이트의 제조방법
US4512994A (en)	1985-04-23	Long-acting theophylline in medicinal form
CA1036618A (en)	1978-08-15	Process for the manufacture of tris (2-hydroxyethyl) ammonium-ortho-cresosyacetate
EP0451760A1 (de)	1991-10-16	Nitratoalkancarbonsäure-Derivate und Verfahren zu ihrer Herstellung
US4189499A (en)	1980-02-19	Lysine 4-allyloxy-3-chlorophenylacetate and method of its preparation
Proskouriakoff	1933	Some Salts of Levulinic Acid1
CZ695188A3 (en)	1993-07-14	ENOL ETHER OF 1,1-DIOXIDE OF 6-CHLORO-4-HYDROXY-2-METHYL-N- (2-PYRIDYL-2H-THIENO(2,3-c)-1,2-THIAZINECARBOXYLIC ACID AMIDE, PROCESS OF ITS PREPARATION AND ITS USE
US3824243A (en)	1974-07-16	Mono-o-phthalyl piperazine and mono-piperazine mono-phthalate di-salts
JPS5910563A (ja)	1984-01-20	α−（Ｎ−ピロリル）−フエニル酢酸誘導体およびその製造方法
Tatsumi et al.	1966	The Preparation of Four Optically Active Isomers of 3-Methylmalic Acid
US3255208A (en)	1966-06-07	Dimethyl-beta-propiothetin and related compounds
KR830002843B1 (ko)	1983-12-27	알킬-케토헥소 피라노사이드 유도체의 제조방법
US3461211A (en)	1969-08-12	Lipotropic compositions and their administration
US4443458A (en)	1984-04-17	Aminocrotonyl 3,5-dinitropyridine useful as adjuncts to radiation therapy